Showing results (561-570 of 4,634) with videos related to
Sort By:
Pageof 464
Anti-Cancer Drugs|May 2, 2000
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agentsT Ollikainen, A Knuuttila, S Suhonen, et al.Anti-Cancer Drugs|May 2, 2000
Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility studyT Ruotsalainen, M Halme, O P Isokangas, et al.Anti-Cancer Drugs|May 2, 2000
Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancerA Hubert, O Lyass, D Pode, et al.Anti-Cancer Drugs|January 25, 2003
Inducing cancer cell death by targeting transcription factorsRyungsa Kim, Kazuaki Tanabe, Manabu Emi, et al.Anti-Cancer Drugs|January 25, 2003
In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazinePeter W Gout, Chris R Simms, May C RobertsonAnti-Cancer Drugs|January 25, 2003
Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibodyNaomi R Schechter, David J Yang, Ali Azhdarinia, et al.Anti-Cancer Drugs|January 25, 2003
A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targetingSanjeev Sewak, Abraham Chachoua, Anne Hamilton, et al.Anti-Cancer Drugs|February 6, 2003
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidantsLars Engman, Nawaf Al-Maharik, Michael McNaughton, et al.Anti-Cancer Drugs|October 24, 2002
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancerStefan Fuxius, Klaus Mross, Kambiz Mansouri, et al.Anti-Cancer Drugs|October 24, 2002
Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gelsFrank Güthlein, Angelika M Burger, Martin Brandl, et al.Pageof 464